Arigen Pharmaceuticals, Inc.
- Country
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)
Phase 2
- Conditions
- Herpes ZosterPostherpetic Neuralgia
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- aRigen Pharmaceuticals, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00652184
- Locations
- 🇺🇸
ARYS-0701 Site 12, Raleigh, North Carolina, United States
🇺🇸ARYS-0701 Site 3, Beverly Hills, California, United States
🇺🇸ARYS-0701 Site 4, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath